Falciparum but not vivax malaria increases the risk of hypertensive disorders of pregnancy in women followed prospectively from the first trimester

Whitney E. Harrington1,2,3, Kerryn A. Moore4,5, Aung Myat Min1, Mary Ellen Gilder1, Nay Win Tun1, Moo Kho Paw1, Jacher Wiladphaingern1, Stephane Proux1, Kesinee Chotivanich6, Marcus J. Rijken7,8, Nicholas J. White9,10,François Nosten1,9 and Rose McGready1,9*

Abstract

Background: Malaria and hypertensive disorders of pregnancy (HDoP) affect millions of pregnancies worldwide, particularly those of young, first-time mothers. Small case-control studies suggest a positive association between falciparum malaria and risk of pre-eclampsia but large prospective analyses are lacking.

Methods: We characterized the relationship between malaria in pregnancy and the development of HDoP in a large, prospectively followed cohort. Pregnant women living along the Thailand-Myanmar border, an area of low seasonal malaria transmission, were followed at antenatal clinics between 1986 and 2016. The relationships between falciparum and vivax malaria during pregnancy and the odds of gestational hypertension, pre-eclampsia, or eclampsia were examined using logistic regression amongst all women and then stratified by gravidity.

Results: There were 23,262 singleton pregnancies in women who presented during the first trimester and were followed fortnightly. Falciparum malaria was associated with gestational hypertension amongst multigravidae (adjusted odds ratio (AOR) 2.59, 95%CI 1.59–4.23), whereas amongst primigravidae, it was associated with the combined outcome of pre-eclampsia/eclampsia (AOR 2.61, 95%CI 1.01–6.79). In contrast, there was no association between vivax malaria and HDoP.

Conclusions: Falciparum but not vivax malaria during pregnancy is associated with hypertensive disorders of pregnancy.

Keywords: First trimester, Falciparum malaria, Pre-eclampsia, Gestational hypertension, Vivax malaria
Background

Worldwide, hypertensive disorders of pregnancy (HDoP) are estimated to affect 3–10% of all pregnancies [1–3], with the greatest risk in the first pregnancies of young women [4]. The clinical presentation ranges from gestational hypertension to pre-eclampsia to life-threatening eclampsia [1]. It is unclear whether gestational hypertension and pre-eclampsia are separate entities or represent a spectrum of disease as they share some but not all risk factors and result in varying placental pathology, with findings consistent with placental ischemia specifically associated with pre-eclampsia [5]. In contrast, eclampsia, or maternal seizures, is considered to be the central nervous system-specific presentation of severe pre-eclampsia [6]. Maternal spiral arteries undergo extensive remodeling during a key window of 6 to 20 weeks’ gestation allowing for appropriate perfusion of the placenta [7]. Accumulating evidence suggests that pre-eclampsia is the product of abnormal spiral artery development leading to placental hypoxia, triggering the release of fetal-derived molecules that increase maternal blood pressure and perfusion of the placenta but result in diffuse endothelial dysfunction in the mother [4].

Primigravidae are also particularly susceptible to *Plasmodium falciparum* malaria in pregnancy with a peak of detection at 13–18 weeks’ gestation in higher transmission settings [8], corresponding to the key period of fetal trophoblast invasion and maternal spiral artery transformation [9]. Falciparum malaria early in pregnancy has been associated with abnormal placental vascular development [10], and falciparum-infected erythrocytes may sequester in the placental intervillous spaces, a condition known as placental malaria, leading to inflammatory infiltrates and low birth weight [11]. Peripheral falciparum malaria in the absence of placental infection has also been associated with poor pregnancy and birth outcomes including miscarriage [12]; pre-term delivery [13]; intrauterine growth retardation [14], small for gestational age [13], and low birth weight [15]; stillbirth [16]; and neonatal death [16]. In contrast, *Plasmodium vivax* malaria does not display a placental tropism, but in the present study area, has also been associated with poor pregnancy outcomes similar to the effect of falciparum malaria [12, 13, 16].

In West Africa, an increase in pre-eclampsia [17] and maternal deaths due to eclampsia has been noted during [18, 19] or immediately after [20] the malaria transmission season. Small studies have linked placental falciparum malaria infection, particularly in young primigravidae [21], with gestational hypertension [21, 22] and pre-eclampsia [17, 23]. Molecular mediators of pre-eclampsia have also been associated with falciparum malaria [21, 24]. Other studies, however, have not found an association between peripheral [25] or placental [26] falciparum malaria and pre-eclampsia. No studies have examined the association between vivax malaria or other human malarial and HDoP. We hypothesized that peripheral falciparum malaria, but not vivax malaria, would increase the risk of HDoP via its effect on placental function and that this effect would be most pronounced with infections occurring early in pregnancy during the key window of placental vascular development.

We therefore examined the association between falciparum and vivax malaria in pregnancy and HDoP along the Thailand-Myanmar border, an area of low seasonal malaria transmission, in a large cohort of women who attended antenatal clinics regularly from the first trimester of pregnancy.

Methods

Cohort and antenatal care

The Shoklo Malaria Research Unit (SMRU) has worked with displaced persons since 1986 and migrant populations since 1998. Clinics are situated along the Thailand-Myanmar border and offer free antenatal and birth care. Antenatal records of singleton births occurring at or after 28 weeks’ gestation between 1986 and 2016 were obtained. The analysis was restricted to women who began antenatal attendance in the first trimester (<14 weeks’ gestation). Women were encouraged to attend an antenatal clinic (ANC) weekly when malaria transmission was high, and fortnightly as transmission decreased, and to attend at any time if ill. The woman’s age, parity, refugee status, number of consultations, weight at enrollment, weight gain during pregnancy, location and year of delivery, and birth outcome were recorded. Data on smoking in pregnancy were obtained between 1997 and 2016. Gestational age was assessed preferentially by ultrasound biometry (2001 to 2016) but if not available by Dubowitz Gestational Age Assessment (1992–2002) and finally by fundal height (1986–1994). As there are no safe and effective chemoprophylactics for pregnant women in settings of multidrug-resistant *P. falciparum*, malaria was detected actively by blood smears obtained at each ANC visit. Hematocrit was also assessed at each visit; moderate and severe anemia was defined as <30% and <20%, respectively. Blood pressure (BP) was measured by a manual sphygmomanometer with the woman recumbent. BP was monitored at least monthly, weekly in the last 4 weeks of pregnancy, and at every malaria episode. A high blood pressure reading was confirmed by repeating the reading after 30 min to confirm that the blood pressure remained elevated after the woman was allowed to relax. Proteinuria by urine dipstick was assessed if BP was elevated (systolic BP ≥ 140 and/or diastolic BP ≥ 90 mmHg).
Clinical information
From the first ANC visit to delivery, vitamin supplements were provided: non-anemic women received iron (ferrous sulfate 200 mg daily), folic acid (5 mg weekly), and vitamin B1 (100 mg daily). Women with anemia received higher doses of ferrous sulfate (400 mg twice daily) and folic acid (5 mg daily) as well as vitamin C and vitamin B12 (both 100 mg twice daily).

Clinical definitions
Throughout the many years of the study, a rigorous and consistent definition of the clinical syndromes was used.

Hypertension
Hypertension was two confirmed episodes of high blood pressure > 6 h apart with systolic BP ≥ 140 or diastolic BP ≥ 90.

Chronic hypertension
Chronic hypertension was hypertension by medical history or documented before 20 weeks’ gestation.

Gestational hypertension
Gestational hypertension was new hypertension that occurred after 20 weeks’ gestation with no/trace of proteinuria.

Pre-eclampsia
Pre-eclampsia was new onset hypertension that occurred after 20 weeks’ gestation with proteinuria (≥1+ on a dipstick), without alternative explanation. For women with a history of chronic hypertension, the onset of new proteinuria was after 20 weeks’ gestation.

Eclampsia
Eclampsia was observed generalized convulsion (i.e., “fitting”) in a pregnant woman without other clear explanation, with a record of proteinuria or hypertension.

Hypertensive disorder of pregnancy
Hypertensive disorder of pregnancy was a combined outcome of gestational hypertension, pre-eclampsia, or eclampsia.

Malaria exposure
Malaria was defined as the presence of asexual parasites on a blood smear. *Plasmodium* species and parasitemia were determined by microscopy for all positive smears. All malaria infections were treated irrespective of symptoms; *P. falciparum* was treated with quinine or artesiminin-based combination therapy, and *P. vivax* was treated with chloroquine. The majority of treatments were supervised. Women with positive blood smears were followed with daily malaria smear until negative. Recurrence or reinfection after treatment completion and negative blood smear was considered possible from day 7 after the primary diagnosis.

Statistical analysis
Each woman was considered in a single outcome category (no HDoP, gestational hypertension, pre-eclampsia, or eclampsia) according to the maximum signs and symptoms she experienced during the pregnancy. For example, if a woman first developed gestational hypertension but later developed proteinuria, she was considered as a final diagnosis of pre-eclampsia; if she went on to develop seizures, she was considered as a final diagnosis of eclampsia. For analyses of falciparum malaria, women with only *P. falciparum* detected during the pregnancy represented the exposed group, regardless of the number of infections, and women with no *Plasmodium* of any species detected served as the control group. The same approach was taken for the analysis of vivax malaria. Given the likely placental origin of HDoP, we restricted the analysis to women who experienced infection after 6 weeks of gestation. Logistic regression was used to estimate the association between falciparum and vivax malaria in pregnancy and each outcome separately. As eclampsia is considered to be a feature of severe pre-eclampsia and there were relatively few eclampsia outcomes, we additionally considered the composite outcome of pre-eclampsia or eclampsia. Models were adjusted for confounding variables: gravidity, maternal age, population (migrant versus refugee), first-trimester weight, pregnancy weight gain, chronic hypertension, year, and place of delivery. Women with pre-pregnancy hypertension were excluded from the model of gestational hypertension. First-trimester weight was used in place of body mass index (BMI) as height was available for a limited number of women (Additional file 1). To assess for confounding by smoking, a subset analysis was conducted amongst women for whom smoking data were available (Additional file 2). Because of prior reports of a gravidity-specific relationship between falciparum malaria and HDoP, accentuated amongst young women [21], we evaluated an interaction term between malaria and gravidity to generate the gravidity-specific effect for each outcome, as well as an interaction term between malaria, gravidity, and maternal age.

To determine if the association between malaria and HDoP was modified by the gestational age at first detection, we added an interaction term between malaria and the gestational age of the first detection as a continuous variable to the adjusted models. The assumption that the change in the association between malaria and the outcome across levels of gestational age was linear was tested visually by plotting the estimated log odds ratios within 4-week gestational age windows and statistically
by including an interaction with gestational age as a quadratic term. We also included an interaction between malaria and gravidity as in the primary analysis, but we did not let the interaction between malaria and gestational age be modified by gravidity as there was no evidence that this interaction was different between primigravidae and multigravidae.

Results

Prevalence of malaria and hypertensive disorders of pregnancy

Of 51,913 women who delivered at or after 28 weeks’ gestation between 1986 and 2016, 23,262 (45%) began antenatal care in their first trimester and had a singleton pregnancy (Fig. 1). Most women, 19,424 (83.5%), did not have malaria detected during their pregnancy. A total of 1047 women (4.5%) had falciparum malaria only with the first detection at or after 6 weeks’ gestation, and 1733 (7.5%) had vivax malaria only with the first detection at or after 6 weeks’ gestation; these three groups (22,204 total women) comprised the final cohort for analysis. An additional 1058 (4.5%) women had falciparum or vivax malaria before 6 weeks’ gestation, infections with multiple species, mixed infections, *P. ovale*, *P. malariae*, or infection with unknown species and were excluded from the analysis.

Women presented to antenatal care early in their pregnancy (median 9 weeks) and delivered with a median gestational age at delivery of 39 weeks (Table 1). The median gestational age at the first detection of falciparum malaria was 16 weeks (Additional file 3), and 759 (72.5%) women had a single episode (the maximum was 6 discrete episodes). The median gestational age at the first detection of vivax malaria was 16 weeks (Additional file 3), and 960 (55.4%) women had a single episode only (the maximum was 8 discrete episodes). Gestational age when malaria was first detected was inversely correlated with the number of episodes.

Women with malaria were more likely to be migrants, anemic, weigh less during the first trimester, gain less weight during the pregnancy, and deliver at home (Table 1). These patterns suggest that women with malaria during pregnancy had less access to health care.

Association between falciparum malaria and hypertensive disorders of pregnancy

The overall risk of HDoP was low; most women, 21,168 (95.3%), did not become hypertensive, 620 (2.8%) had gestational hypertension, 346 (1.6%) had gestational hypertension, 346 (1.6%) had pre-eclampsia,
and 43 (0.2%) had eclampsia. Falciparum malaria during pregnancy was associated with gestational hypertension in multigravidae (AOR 2.59, 95%CI 1.59–4.23, p < 0.001) but not primigravidae (Fig. 2). In contrast, amongst primigravidae but not multigravidae, there was an association with pre-eclampsia (AOR 2.67, 95%CI 0.92–7.71, p = 0.07) which was statistically significant when assessing the combined outcome of pre-eclampsia/eclampsia (AOR 2.61, 95%CI 1.01–6.79, p = 0.048) (Fig. 2). The effect was greatest amongst young (< 20 years) primigravidae (pre-eclampsia: AOR = 3.64, 95%CI 1.04–12.79, p = 0.044; pre-eclampsia/eclampsia: AOR 3.23, 95%CI 1.07–9.75, p = 0.038).

Association between falciparum malaria and hypertensive disorders of pregnancy by gestational age of falciparum malaria

As abnormalities in spiral artery remodeling are associated with subsequent HDoP, we specifically considered whether the effects described above varied by gestational age of the first detection of falciparum malaria. For all outcomes, there was a non-significant interaction with the gestational age of the first detection, whereby the association between falciparum malaria in pregnancy and HDoP was greater in early pregnancy than in late pregnancy (Fig. 3). When these models were used to calculate the predicted effect sizes at the beginning of the 2nd (14 weeks’ gestation) and 3rd (28 weeks’ gestation) trimesters, the associations between falciparum malaria and gestational hypertension in multigravidae and pre-eclampsia/eclampsia in primigravidae were more significant at 14 weeks (gestational hypertension amongst multigravidae: AOR = 2.36, 95%CI 1.37–4.09, p = 0.002; pre-eclampsia/eclampsia amongst primigravidae: AOR 2.88, 95%CI 1.08–7.64, p = 0.034) than at 28 weeks (gestational hypertension amongst multigravidae: AOR 1.95, 95%CI 1.01–3.77, p = 0.05; pre-eclampsia/eclampsia amongst primigravidae: AOR 1.94, 95%CI 0.54–6.94, p = 0.31) (Additional file 4).

Table 1 Participant characteristics by Plasmodium exposure

| Characteristic                     | No malaria | P. falciparum | P. vivax |
|-----------------------------------|------------|--------------|---------|
| Number                            | 19,424     | 1047         | 1733    |
| Maternal age, years, mean (SD)    | 26.2 (6.5) | 25.2 (6.2)   | 25.4 (6.7) |
| Gravidity, n (%)                  |            |              |         |
| Primi                             | 4898 (25.2%)| 270 (25.8%)  | 507 (29.3%) |
| Multi                             | 14,526 (74.8%)| 777 (74.2%)  | 1226 (70.7%) |
| Refugee status, n (%)             |            |              |         |
| Refugee                           | 14,393 (74.1%)| 592 (56.5%)  | 707 (40.8%) |
| Migrant                           | 4450 (22.9%)| 362 (34.6%)  | 951 (54.9%) |
| Visitor (to refugee camp)         | 580 (3.0%) | 93 (8.9%)    | 75 (4.3%) |
| EGA first ANC, weeks, median (range)| 9 (–1–14)a| 10 (0–14)   | 9 (0–14) |
| Anemia at first ANC, n (%)        |            |              |         |
| None                              | 17,652 (95.5%)| 777 (83.9%)  | 1569 (92.9%) |
| Moderate                          | 825 (4.5%) | 148 (16.0%)  | 120 (7.1%) |
| Severe                            | 3 (0.02%) | 1 (0.1%)     | 0 (0%) |
| First trimester weight, kg, mean (SD) | 48.0 (7.7)  | 46.5 (6.1)  | 46.7 (6.8) |
| Weight gain, kg, mean (SD)        | 9.0 (3.9) | 8.0 (3.6)    | 8.2 (3.6) |
| Chronic HTN, n (%)                |            |              |         |
| No                                | 19,266 (99.2%)| 1040 (99.3%)| 1723 (99.4%) |
| Yes                               | 158 (0.8%) | 7 (0.7%)     | 10 (0.6%) |
| Number of consultations, median (range) | 20 (1–43) | 19 (1–37)  | 22 (1–38) |
| Year of delivery, median (range)  | 2007 (1986–2016) | 2000 (1987–2015) | 2006 (1987–2016) |
| EGA delivery, weeks, median (range) | 39 (28–44) | 39 (28–45)  | 39 (28–44) |
| Place of delivery                 |            |              |         |
| Home                              | 4920 (25.3%)| 576 (55.0%)  | 730 (42.1%) |
| SMRU                              | 12,909 (66.5%)| 441 (39.3%)  | 815 (47.0%) |
| Hospital                          | 1595 (8.2%)| 60 (5.7%)    | 188 (10.9%) |

SD standard deviation, EGA estimated gestational age, ANC antenatal clinic, HTN hypertension, SMRU Shoklo Malaria Research Unit (SMRU) 
a(−1) permitted given known margins of error of this measurement
Association between falciparum malaria and hypertensive disorders of pregnancy restricted to women with a single episode

Because of the inverse correlation between gestational age at the first episode and the number of falciparum episodes, we performed a sensitivity analysis in which we restricted evaluation to those women who had only a single detected episode compared to those who had no detected episodes. This attenuated the relationship between falciparum malaria and gestational hypertension amongst multigravidae (AOR 1.68, 95%CI 0.87–3.27, p = 0.126) suggesting a dose effect. The relationship between falciparum malaria and pre-eclampsia/eclampsia amongst primigravidae was preserved (AOR 3.04, 95%CI 1.07–8.70, p = 0.038).

Association between vivax malaria and hypertensive disorders of pregnancy

In contrast to falciparum malaria, there was no association between vivax malaria and any outcome, nor was there any evidence of effect modification by gravidity (Figs. 4 and 5).

Discussion

This study is the largest, prospective analysis of the relationship between falciparum and vivax malaria in pregnancy and HDoP with more than 20,000 pregnancies followed from the first trimester. It was conducted in an area of low seasonal transmission in epidemiological conditions in which symptomatic malaria in pregnancy is common and severe falciparum malaria a significant risk. We found that falciparum malaria was associated with gestational hypertension in multigravidae but not primigravidae. This effect was greater with multiple episodes. In contrast in primigravidae, there was a significant association between falciparum malaria and pre-eclampsia or eclampsia which was not seen in multigravidae. There was some indication that the effect of falciparum malaria was greater when the infection occurred early in pregnancy, but this was not conclusive. These observations are consistent with falciparum malaria impacting spiral artery development and emphasize the importance of malaria prevention early in pregnancy.

There is some evidence that systemic infections may trigger pre-eclampsia, although findings are mixed [27, 28]. Some, but not all, studies from Africa, where...
malaria transmission is substantially higher and most women with malaria in pregnancy are asymptomatic, have described an association between falciparum placental malaria diagnosed at delivery and HDoP [17, 21–23, 26]. In contrast, we describe the risk associated with treated peripheral falciparum malaria. In this setting, with frequent active screening and treatment infections are cleared rapidly, and there is essentially no placental malaria at delivery. However, despite prompt diagnosis and treatment, falciparum malaria early in pregnancy is associated with poor outcomes including miscarriage [12], small for gestational age [13], low birth weight [15], and pre-term delivery [15], and there is accumulating evidence suggesting that falciparum malaria early in gestation may alter placentation and spiral artery remodeling, leading to chronic placental hypoxia and alterations in the placental structure [10, 14, 29].

In this study, there was evidence of effect modification by gravidity. A previous study demonstrated an association between placental malaria and hypertension specifically in young primigravidae [21]. Primigravidae are at the greatest risk of pre-eclampsia [1] as well as falciparum malaria during pregnancy [30]. When infected, they may therefore be more susceptible to the “triggering” of a pre-eclampsia phenotype [30]. By contrast, multigravidae are more resistant to malaria infection and may be more resistant to the triggering of pre-eclampsia, ultimately leading to the milder presentation of gestational hypertension. Supporting the notion of a stronger stimulus required to trigger the phenotype

Fig. 3 Gestational age of the first detection of falciparum malaria to predict hypertensive disorders of pregnancy. Black line: all women; blue line: primigravidae, yellow line: multigravidae. Dashed curves represent 95% confidence intervals. There was a non-significant interaction between gestational age and falciparum infection for both gestational hypertension (a) and pre-eclampsia/eclampsia (b), such that infections early in pregnancy had the greatest impact.
amongst multigravidae, the sensitivity analysis suggested that repeat falciparum infections increased the risk of gestational hypertension. Alternatively, gestational hypertension and pre-eclampsia may be driven by different pathologic perturbations, where gestational hypertension in multigravidae may represent a disease of systemic vasculature, rather than a placental-origin disease [5].

In contrast to falciparum malaria, no increased risk of HDoP was conferred by vivax malaria. The lack of association between vivax malaria, also a systemic infection, and HDoP is striking, especially given that there were nearly twice as many episodes of vivax malaria detected relative to falciparum malaria, so the power to detect an association should have been high. In this area, vivax in pregnancy is associated with an increased risk of miscarriage, preterm birth, stillbirth, small for gestational age, and neonatal mortality [13, 16, 31]. However, vivax malaria does not result in severe multisystem disease, and although in vitro it has been shown to cytoadhere to chondroitin sulfate A [32], a placental ligand, it does not sequester significantly in the placenta or alter trophoblast invasion [33]. We hypothesize that the effect of falciparum, but not vivax, malaria on placental vascular development and function may lead to increased risk of HDoP. Alternatively, chloroquine, the treatment of vivax malaria, has inherent anti-inflammatory properties which may have been protective against the triggering of HDoP [34, 35].

This study has a number of limitations. First, as an observational cohort study over 30 years, there may be factors outside of malaria incidence [13] that varied over time, which we accounted for by adjusting for the year of delivery. In addition, we utilized the older definition of pre-eclampsia (hypertension plus proteinuria), as we had limited clinical information to define other markers of end-organ dysfunction, and clinically, this definition guided treatment. The rates of hypertensive disorders we describe are similar to those reported previously from Asia [2, 3]. Further, when considering the effect of timing of malaria episodes, we considered only the first detection. Most malaria infections occurred early in gestation, increasing the confidence intervals around the estimates of the effect in later pregnancy. In addition, similar to other developing world populations, the numbers of primigravidae relative to multigravidae were relatively small, and confidence intervals were wide. We have attempted to control for known potential confounders, but there may be other non-assessed residual confounders. Importantly, women with malaria likely had less access to care and were more likely to deliver at home, suggesting that the diagnosis of HDoP may

| Table 4 Association between vivax malaria and hypertensive disorders of pregnancy. Vivax malaria was not associated with risk of hypertensive disorders of pregnancy. |
|---------------------------------------------------------------|
|                         | Yes P. vivax (n/N) | No P. vivax (n/N) | AOR (95% CI); p-value |
|--------------------------|-------------------|-------------------|----------------------|
| Gestational Hypertension |                   |                   |                      |
| All women                | 25/1399           | 537/16476         | 0.78 (0.51, 1.18); p = 0.236 |
| Primigravidae            | 8/163             | 411/4414          | 0.72 (0.35, 1.48); p = 0.372 |
| Multigravidae            | 17/980            | 382/12318         | 0.81 (0.49, 1.54); p = 0.404 |
| Pre-eclampsia            |                   |                   |                      |
| All women                | 18/1392           | 269/16233         | 0.76 (0.45, 1.28); p = 0.304 |
| Primigravidae            | 4/415             | 78/4083           | 0.52 (0.19, 1.41); p = 0.179 |
| Multigravidae            | 14/977            | 191/12150         | 0.90 (0.48, 1.66); p = 0.727 |
| Eclampsia                |                   |                   |                      |
| All women                | 2/1376            | 33/15972          | 0.77 (0.18, 3.32); p = 0.730 |
| Primigravidae            | 2/413             | 16/4019           | 1.36 (0.30, 6.18); p = 0.688 |
| Multigravidae            | 0/963             | 17/11953          | Not calculable |
| Pre-eclampsia or Eclampsia |                  |                   |                      |
| All women                | 20/1394           | 302/16266         | 0.76 (0.46, 1.25); p = 0.287 |
| Primigravidae            | 6/417             | 94/4099           | 0.68 (0.29, 1.63); p = 0.388 |
| Multigravidae            | 14/977            | 208/12167         | 0.81 (0.45, 1.48); p = 0.498 |

Fig. 4 Association between vivax malaria and hypertensive disorders of pregnancy. Vivax malaria was not associated with risk of hypertensive disorders of pregnancy.
be underestimated in this group. This, combined with prompt detection and treatment of all malaria episodes, suggests that the association between malaria and HDoP reported here is likely to be a conservative estimate of the true effect.

**Conclusions**

The data from these women prospectively followed from the first trimester suggest that *P. falciparum* malaria may result in chronic placental hypoxia, eventually progressing to clinical gestational hypertension or pre-eclampsia. Worldwide, most malaria prevention strategies are not implemented until the beginning of the second trimester or later, leaving women at risk of infection early in gestation. These data highlight the critical need to prevent malaria early in pregnancy, particularly amongst primigravidae who are most vulnerable to the severe outcome of pre-eclampsia.

**Abbreviations**

ANC: Antenatal clinic; AOR: Adjusted odds ratio; BMI: Body mass index; BP: Blood pressure; HDoP: Hypertensive disorders of pregnancy; SMRU: Shoklo Malaria Research Unit

**Supplementary Information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12916-021-01960-3.

Additional file 1: Table S1. *P. falciparum* to predict HDoP among women with data on body mass index from enrollment (n=14,590).

Additional file 2: Table S2. *P. falciparum* to predict HDoP among women with known smoking status between 1997-2016 (n=19,049).
Acknowledgements
Sincere thanks to the pregnant women who attended antenatal care and the dedicated staff at SMRU who provided antenatal care and 24-h coverage for childbirth, as well as consistent and solid data collection.

Authors’ contributions
WEH and RM—literature search, study design, data collection, data analysis and interpretation, writing of the manuscript, and verification of the underlying data. KM—study design, data analysis and interpretation, figure generation, and writing of the manuscript. MEG—data collection and writing of the manuscript. MR, NW, and FN—data interpretation and writing of the manuscript. AMM, NWT, MKP, JW, SP, and KC—data collection. All authors had full access to the full data in the study and accept responsibility to submit for publication. The authors read and approved the final manuscript.

Funding
This research was funded in part by the Wellcome-Trust Major Overseas Programme in Southeast Asia [WT-106698]. For the purpose of open access, the author has applied a CC BY public copyright license to any author accepted manuscript version arising from this submission; WEH was supported by the National Institutes of Health/National Institute of Allergy and Infectious Diseases (K08 AI135072), Burnoughs Wellcome Fund (CAWS 1017213), and the American Society for Tropical Medicine and Hygiene with a Benjamin H. Kean Travel Fellowship.

Availability of data and materials
The data used to support the findings of this study may be released upon application to the Data Access Committee at Mahidol-Oxford Tropical Medicine Research Unit (MORU); contact at https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing.

Declarations

Ethics approval and consent to participate
The Oxford Tropical Research Ethics Committee granted ethical approval for audits of SMRU clinical records (OXTREC 28-09), and the Tak Province Community Advisory Board provided local permission (T-CAB-4/1/2015).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand.
2 Department of Pediatrics, University of Washington, Seattle, WA, USA.
3 Seattle Children’s Research Institute, Seattle, WA, USA.
4 London School of Hygiene and Tropical Medicine, London, UK.
5 Murdoch Children’s Research Institute, Melbourne, Australia.
6 Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
7 Utrecht University Medical Centre, Utrecht, the Netherlands.
8 Julius Centre Global Health, Utrecht, the Netherlands.
9 Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford, UK.
10 Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Received: 9 December 2020 Accepted: 16 March 2021
Published online: 27 April 2021

References
1. Hypertension in Pregnancy, Obstetrics & Gynaecology. 2013;22(5):1122–31. https://doi.org/10.1097/01.AOG0000000000003382.
2. Abalos E, Cuesta C, Caroli G, Qureshi Z, Widmer M, Vogel JP, Souza JP, Maternal WHOMSo, Newborn Health Research N: Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG 2014, 121 Suppl 1:14–24, https://doi.org/10.1111/1471-0528.12629.
3. Bilanso V, Ota E, Ganchimeg T, Mori R, Souza JP. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis. PLoS One. 2014;9(9):e119198. https://doi.org/10.1371/journal.pone.0119198.
4. Chaiworrapongsa T, Chaemsaiithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014; 10(8):466–80. https://doi.org/10.1038/nrneph.2014.102.
5. Melamed N, Ray JG, Hladunewich M, Cox B, Kingdom JC. Gestational hypertension and preeclampsia: are they the same disease? J Obstet Gynaecol Can. 2014;36(6):642–7. https://doi.org/10.1016/j.jogc.2013.10.015.
6. Peres GM, Mariana M, Caiaro E: Pre-eclampsia and eclampsia: an update on the pharmacological treatment applied in Portugal. J Cardiovasc Dev Dis 2018;5(1):3. https://doi.org/10.3390/jcd5010003.
7. Degner K, Magness RR, Shah DM. Establishment of the human uteroovarian circulation: a historical perspective. Reprod Sci. 2017;24(5):753–61. https://doi.org/10.1177/193739741669056.
8. Brabin BJ. An analysis of malaria in pregnancy in Africa. Bull World Health Organ. 1983;61(6):1005–16.
9. Pereira RO, De Long NE, Wang RC, Yazdi FT, Holloway AC, Raha S. Angiogenesis in the placenta: the role of reactive oxygen species signaling. Biomed Res Int. 2015;2015:814543.
10. Moeller SL, Nyengaard JR, Larsen LG, Nielsen K, Bygbjerg IC, Msmo OA, Lusingu JPA, Minja DTR, Theander TG, Schmiegelow C. Malaria in early pregnancy impedes the development of the placental vasculature. J Infect Dis. 2019;220(9):1424–35. https://doi.org/10.1093/infdis/jjy335.
11. Brabin BJ, Romagosa C, Abdegail SJ, Wemyss C, Verhoef H, Mcgregor R, Fletcher KA, Ovens S, D’Alessandro U, Nosten F, et al. The sick placenta-the role of malaria. Placenta. 2004;25(5):359–78. https://doi.org/10.1016/j.placenta.2003.10.019.
12. Mcgregor R, Lee SJ, Wilладphaingern J, Ashley EA, Rijken MJ, Boel M, Simpson JA, Paw MK, Pimanpanarak M, Mu O, Singshaivanon P, White NJ, Nosten FH. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis. 2012;12(5):388–96. https://doi.org/10.1016/S1473-3099(11)70339-5.
13. Moore KA, Simpson JA, Wilладphaingern J, Min AM, Pimanpanarak M, Paw MK, Raksuansak J, Pukrittayakamee S, Fowkes FJ, White NJ, Nosten F, Mcgregor R. Influence of the number and timing of malaria episodes during pregnancy on prematurity and small-for-gestational-age in an area of low transmission. BMC Med. 2017;15(1):117. https://doi.org/10.1186/s12916-017-0877-6.
14. Griffin JB, Lokomba V, Landis SH, Thorp JM Jr, Herring AH, Tshefu AK, Rogerson SJ, Meshnick SR. Plasmodium falciparum parasitaemia in the first half of pregnancy, uterine and umbilical artery blood flow, and foetal growth: a longitudinal Doppler ultrasound study. Malar J. 2012;11(1):319. https://doi.org/10.1186/1475-2875-11-319.
15. Schmiegelow C, Matondo S, Minja DTR, Resende M, Pehson C, Nielsen BB, Oلونi R, Nielsen MA, Deloron P, Salanti A, Lusingu J, Theander TG. Plasmodium falciparum infection early in pregnancy has profound consequences for fetal growth. J Infect Dis. 2017;216(12):1601–10. https://doi.org/10.1093/infdis/jix530.
16. Moore KA, Fowkes FJ, Wilладphaingern J, Wai NS, Paw MK, Pimanpanarak M, Carrara VI, Raksuansak J, Simpson JA, White NJ, Nosten F, Mcgregor R. Mediation of the effect of malaria in pregnancy on stillbirth and neonatal death in an area of low transmission: observational data analysis. BMC Med. 2017;15(1):98. https://doi.org/10.1186/s12916-017-0863-z.
17. Sartelet H, Rogier C, Milko-Sartelet I, Angel G, Michel G. Malaria associated pre-eclampsia in Senegal. Lancet. 1996;347(9008):1121. https://doi.org/10.1016/s0140-6736(96)81021-9.
18. Anya SE. Seasonal variation in the risk and causes of maternal death in the Gambia: malaria appears to be an important factor. Am J Trop Med Hyg. 2004;70(5):510–3. https://doi.org/10.4269/ajtmh.2004.70.510.
19. Etard JF, Kodio B, Ronciman C. Seasonal variation in direct obstetric mortality in rural Senegal: role of malaria? Am J Trop Med Hyg. 2003;68(4):503–4. https://doi.org/10.4269/ajtmh.2003.68.503.
20. Hounton SH, Sombie I, Townend J, Ouedraogo T, Meda N, Graham WJ. The tip of the iceberg: evidence of seasonality in institutional maternal mortality and implications for health resources management in Burkina Faso. Scand J Public Health. 2008;36(3):310–7. https://doi.org/10.1177/1403494807085361.

21. Muehlenbachs A, Mutasingwwa T, Edmonds S, Fried M, Duffy PE. Hypertension and maternal-fetal conflict during placental malaria. PLoS Med. 2006;3(11):e446. https://doi.org/10.1371/journal.pmed.0030446.

22. Ndao CT, Dumont A, Fievet N, Doucoure S, Gaye A, Lehessen JY. Placental malarial infection as a risk factor for hypertensive disorders during pregnancy in Africa: a case-control study in an urban area of Senegal, West Africa. Am J Epidemiol. 2009;170(7):847–53. https://doi.org/10.1093/aje/kwp207.

23. Adam I, Elhassan EM, Mohmmed AA, Salih MM, Elbashir MI. Malaria and pre-eclampsia in an area with unstable malaria transmission in Central Sudan. Malar J. 2011;10:258. https://doi.org/10.1186/1475-2875-10-258.

24. Silver KL, Conroy AL, Leke RG, Leke RJ, Gwanmesia P, Molyneux ME, Taylor DW, Rogerson SJ, Kain KC. Circulating soluble endoglin levels in pregnant women in Cameroon and Malawi--associations with placental malaria and fetal growth restriction. PLoS One. 2011;6(9):e24885. https://doi.org/10.1371/journal.pone.0024985.

25. Dorman EK, Shulman CE, Kingdom J, Bulmer JN, Mwendwa J, Peshu N, Marsh K. Impaired uteroplacental blood flow in pregnancies complicated by falciparum malaria. Ultrasound Obstet Gynecol. 2002;19(2):165–70. https://doi.org/10.1046/j.0960-7692.2001.00545.x.

26. Shulman CE, Marshall T, Dorman EK, Bulmer JN, Cutts F, Peshu N, Marsh K. Malaria in pregnancy: adverse effects on haemoglobin levels and birthweight in primigravidae and multigravidae. Tropical Med Int Health. 2001;6(10):770–8. https://doi.org/10.1046/j.1365-3156.2001.00786.x.

27. Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2008;198(1):7–22. https://doi.org/10.1016/j.ajog.2007.07.040.

28. Rustveld LO, Kelsey SF, Sharma R. Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies. Matern Child Health J. 2008;12(2):223–42. https://doi.org/10.1007/s10995-007-0224-1.

29. McClure EM, Meshnick SR, Laeznik N, Mungai P, King CI, Hudgens M, Goldberg RL, Segu-Riz AM, Dent AE. A cohort study of Plasmodium falciparum malaria in pregnancy and associations with uteroplacental blood flow and fetal anthropometrics in Kenya. Int J Gynaecol Obstet. 2014;126(1):78–82. https://doi.org/10.1016/j.ijgo.2014.01.016.

30. Brabin BJ, Johnson PM. Placental malaria and pre-eclampsia through the looking glass backwards? J Reprod Immunol. 2005;65(1):1–15. https://doi.org/10.1016/j.jri.2004.09.006.

31. Moore KA, Simpson JA, Scouller MJL, McGready R, Fowkes FJL. Quantification of the association between malaria in pregnancy and stillbirth: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(11):e1101–12. https://doi.org/10.1016/S2214-109X(17)30340-6.

32. Chotivanich K, Udomsangpetch R, Suwanarusk R, Puikrittyakamee S, Wilaratanakarn P, Beeson KS, Day NP, White NJ. Plasmodium vivax adherence to placental glycosaminoglycans. PLoS One. 2012;7(4):e34509. https://doi.org/10.1371/journal.pone.0034509.

33. McGready R, Davison BB, Stepniewska K, Cho T, Shee H, Brockman A, Udomsangpetch R, Locareesuwan S, White NJ, Meshnick SR, et al. The effects of Plasmodium falciparum and P. vivax infections on placental histopathology in an area of low malaria transmission. Am J Trop Med Hygiene. 2004;70(4):398–407. https://doi.org/10.4269/ajtmh.2004.70.398.

34. Oh S, Shin JH, Jung EJ, Won HY, Kim HK, Jeong MC, Kim KS, Hwang ES. Anti-inflammatory activity of chloroquine and amodiaquine through p21-mediated suppression of T cell proliferation and Th1 cell differentiation. Biochem Biophys Res Commun. 2016;474(2):345–50. https://doi.org/10.1016/j.bbrc.2016.04.105.

35. Silva JC, Mariz HA, Rocha LF Jr, Oliveira PS, Dantas AT, Duarte AL, Pitta Ida R, Galdino SL, Pitta MG. Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (Sao Paulo). 2013;68(6):766–71. https://doi.org/10.6061/clinics/2013(06)07.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.